Key Takeaways
- Worst quarter in memory, driven by paint: Sales volume collapsed ~35% QoQ as decorative paint customers abruptly stopped buying, dragging EBITDA margin to 3.51%. Management insists no customers or products were lost.
- Raw material chaos is normalizing: Unprecedented commodity price swings tied to the Ukraine war have settled at 10–15% above pre-conflict levels, removing the inventory-loss risk that plagued prior quarters.
- A strategic pivot is underway: The company is repurposing Tocopherol-project equipment for a new oleochemical raw material targeting the epoxy industry, aiming to reduce dependence on paint customers by end-CY2024.
- Recovery is directional, not quantified: Demand began reviving in January and management is "fairly confident" volumes will return to original levels, but declined to put numbers on the pace, citing regulatory constraints.
- What to watch next quarter: Whether the January demand recovery sustains into Q4 volumes, the Isostearic plant commissioning timeline holds, and any concrete update on the new epoxy-industry product's commercialization path.
The Paint Demand Shock
- Volume collapse was sudden and severe: Sales volume fell to 9,700 tons from 14,800 tons in Q2, a ~35% sequential drop, driven entirely by decorative paint customers reducing purchases. Management emphasized no customer losses or product replacement occurred.
- Paint companies drew down inventory: Management believes paint companies may have gone slow on purchasing and used up their own inventory, while their consolidated results include auto and industrial segments that did not decline.
- Pricing compounded the volume hit: Realization fell ~10% QoQ as raw material price fluctuations fed through to monthly selling prices, amplifying the revenue decline.
- Customer retention intact: Management stated explicitly they have not lost any paint-company customers, and samples have been under analysis with new entrants like Birla and JSW for the past year.
Nahoosh Jariwala: "the fall in sales has been only and only for the reason and that is the lack of demand from our customers in the paint industry and not because of we losing out on any of our customers or the paint companies replacing our products with some other products."
Margin & Cost Management
- Volume deleverage crushed margins: EBITDA margin fell to 3.51% in Q3 as the substantial volume fall eroded profitability; management called it "one of the worst quarter performance after a very longtime."
- Inventory loss avoided: The company processed only 8,700 tons against purchases of 10,400 tons, selling 9,700 tons partly from carry-over inventory, which insulated them from raw material price declines during the quarter.
- High-cost inventory normalized: The high-cost inventory issue that pressured prior quarters has now worked through the system.
- Structural cost discipline: All costs other than raw material and power/fuel have been economized relative to volume processed or sales value achieved, a focus maintained since April 2010.
- Margin guidance withheld: Management declined to commit to a specific FY24 EBITDA margin percentage, citing raw material and finished goods price volatility since February 2022, but noted 9M FY23 cumulative margin of ~10-11% will "certainly be improving on that."
Management: "the percentage term is very difficult thing to comment on because if the prices remain at this level stable as far as raw material and finished goods are concerned, then it is okay and it actually was the case from 1996 till end of 2021 or even up to March 2022, but thereafter post this February 2022, Russia-Ukraine war, the instability in the last 12 months, the volatility in the pricing that has actually ruined this entire thing"
Strategic Diversification Away from Paint
- New raw material initiative launched: The company will introduce an additional oleochemical-stream raw material using existing equipment, targeting the epoxy industry rather than paint, with commercialization targeted by December 2023 or at most March 2024.
- Tocopherol project may be deferred: Management is considering temporarily deferring the upgraded Tocopherol forward-integration project to repurpose that equipment for the new raw material and finished product, serving a new set of customers distinct from existing paint-segment demand.
- Tocopherol commitment remains: Despite the potential deferral, management stated it is their "ultimate dream" to eventually make pure Tocopherol and Vitamin E, and they have decided to remain in the business, continuing the present low-concentration export stream to three Fortune 500 customers.
- Isostearic plant on track: Commissioning is targeted for the April-June quarter (Q1 FY24), adding another product stream.
- Export volumes building: Small-quantity exports of Linoleic Acid and Dimer Acid have begun, with volumes expected to increase in coming quarters.
Management: "it is our ultimate dream to one day go ahead and make mix Tocopherol's pure 100% and ultimately Vitamin E we have decided to remain in this business."
Raw Material & Competitive Dynamics
- Unprecedented volatility stabilizing: Raw material prices reached nearly 2x pre-February 2022 levels, then fell to ~1.3x, and are now hovering 10–15% above pre-conflict levels. Management noted this is the first such volatility in 25 years.
- Dimer acid competition benign: A new entrant (3F industry, Andhra Pradesh) manufacturing Dimer Acid is expected to replace imports that constitute 35% of the Indian market, rather than threaten Fairchem's ~65% domestic market share.
- Market share ceiling acknowledged: Management believes they can reach up to 75% of India's total market share for a product, with customers typically maintaining at least 25% from alternative suppliers.
- Not a commodity play: Management emphasized the company is a manufacturing company whose core competence is making goods of the right quality at an accepted price, stating "we will never play around in commodity."
Management: "We haven't seen this type of volatility in the last 25 years of our existence. For the first time this is happening, I feel once the things stablize then there should not be anything"
Volume & Realization Outlook
- Recovery underway but unquantified: Demand started reviving in January and management is "fairly confident" production will increase to original levels over time, but declined to share specific January numbers citing UPSI guidelines and NSE investigations.
- Q4 recovery partial: Management cautioned that "no recovery can happen 100%," so Q4 will see recovery from the ~35% drop but not a full return to Q2 levels.
- FY24 vs FY22 benchmark: Management confirmed "for sure" that March FY22 sales levels may be recovered in FY24.
- FY24 topline and bottomline growth: Both topline and bottomline anticipated to be higher than FY23, with absolute numbers expected to keep increasing sequentially.
- Long-term volume trajectory: 11-year average volume growth has never been less than 10-12%, and management hopes to maintain this in years to come.
- Realization mix effects: Average price realization depends on product mix, with Dimer Acid at the high end and Linoleic Acid at the low end, so shifts in demand between products affect per-unit realization independently of raw material prices.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| New epoxy-industry product commercialization | New raw-material-based product for epoxy industry using existing equipment | December 2023 or at most March 2024 |
| Isostearic plant commissioning | Plant to be commissioned | April–June quarter (Q1 FY24) |
| FY24 topline vs FY23 | FY24 topline anticipated higher than FY23 | FY24 |
| FY24 bottomline vs FY23 | FY24 bottomline anticipated higher than FY23 | FY24 |
| FY24 volume vs FY22 | March FY22 sales levels "for sure" recovered | FY24 |
| Tocopherol forward-integration decision | Defer temporarily and pivot equipment to new raw material, or proceed with upgrade | Decision pending; no timeline given |
| Long-term volume growth | Maintain 10-12% average annual volume growth | Years to come |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Operational revenue | ₹102 cr |
| EBITDA | ₹4 cr |
| EBITDA margin | 3.51% |
| Net profit after tax | ₹0.6 cr |
| PAT margin | 0.59% |
| 9M FY23 operational revenue | ₹496 cr |
| 9M FY23 EBITDA | ₹53 cr, EBITDA margin 10.68% |
| 9M FY23 net profit after tax | ₹32 cr, PAT margin 6.37% |
| Sales volume | 9,700 metric tons, down from 14,800 metric tons in Q2 FY23 |
| Sales volume decline QoQ | ~35% |
| Pricing degrowth QoQ | 10% |
| Raw material process quantity | 8,700 tons, down from 16,700 tons in Q2 FY23 |
| Raw material purchase volume | 10,400 tons |
| 9M FY23 Dimer Acid value | ₹130 cr |
| 9M FY23 Linoleic Acid value | ₹234 cr |
| Dimer Acid Indian market share | ~65%, balance 35% from imports |
| Tocopherol share of total sales | 5% |
| Combined share of Linoleic and Dimer Acid in total sales | 70–75% |
| FY23 full-year processing target | 54,000 to 55,000 tons, versus ~59,000 tons in FY22 |
| Raw material price level vs pre-Feb 2022 | 10–15% higher, having peaked at nearly 2x then falling to ~1.3x |